Latest Advances in Lung Cancer Research

Address disparities in lung cancer screening. Abstracts presented at ASCO’s 2021 annual meeting address disparities in lung cancer screening.

Future of liquid biopsy: Analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis.

Bone marrow damage reduced for extended stage small cell lung cancer patients with newly FDA approved Cosela.

Lower risk of brain mets from screening. LDCT Screening linked to lower risk of brain mets for lung cancer patients.

Imfinzi increases five year survival to 43% in patients with Stage III non-small cell lung cancer. After treatment, 43% survive 5+ years.

Dr. Karen Marrone discusses the role of postoperative radiotherapy (PORT) in early-stages of non-small cell lung cancer (NSCLC).

Diverse workforce in oncology: Improvement of inclusion and equity critical to reducing health disparities in cancer care.

No link to outside article.

Immunotherapy + Chemo Boosts Response for NSCLC patients with resectable tumors, new study out of Johns Hopkins University, Baltimore shows.

New NSCLC targeted therapy guidelines have been published. They are updates to the 2017 systemic therapy recommendations.

Immuno-oncology effectiveness in medicare population is the subject of a study of 20,000 Medicare patients published in JAMA.

Immunotherapy for early-stage lung cancer is the focus of a study presented at the American Society of Clinical Oncology (ASCO) annual meeting.